Study M549
Study name | Levitt JG 2019 |
Title | Dorsolateral prefrontal gamma-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy |
Overall design | In this study, proton magnetic resonance spectroscopy (MRS) was used to assess changes in gamma-aminobutyric acid (GABA) levels at the site of repetitive transcranial magnetic stimulation (rTMS) in the left dorsolateral prefrontal cortex (DLPFC). In 26 adults with treatment-resistant depression, we used Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS) spectral-editing MRS to measure GABA in the left DLPFC before and after standard clinical treatment with rTMS. All participants began 5-day-per-week, 6-week rTMS treatment. Water-referenced, CSF-corrected GABA levels were expressed in institutional units. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Treatment-resistant depression; Treatment-resistant depression; |
Criteria for depression | DSM-IV diagnosed MDD |
Sample size | 26 |
Tissue | Central; Brain; Dorsolateral prefrontal cortex; |
Platform | MRS; MRS: 3 T Siemens Prisma; |
PMID | |
DOI | |
Citation | Levitt JG, Kalender G, O’Neill J, et al. Dorsolateral prefrontal gamma-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy. J Psychiatry Neurosci. 2019;44(6):386-394. |
Metabolite |
